Sign In
Last checked at 
9 Jun 2025 07:00
9 June 2025
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Best Paper Award
Third party validation for ChemoSeed
CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to announce it has been selected to receive the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society ("CRS") for its paper "Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumour recurrence in a glioblastoma tumour model".
The award, co-sponsored by CRS and Springer, recognises the most impactful and innovative original research article published in Drug Delivery and Translational Research during the past year. CRISM's winning paper, presents foundational research and preclinical validation for ChemoSeed, CRISM's proprietary localised chemotherapy delivery technology designed to maximise on-target efficacy while minimising systemic toxicity. It highlights ChemoSeed's translational potential as a safe and effective treatment for glioblastoma.
The award was selected by a panel of internationally recognised scientists and will be formally presented at the upcoming CRS Annual Meeting, taking place in Philadelphia, PA in July 2025.
Prof. Chris McConville, Chief Scientific Officer at CRISM and lead author of the paper, commented:
"We are honoured to receive this recognition from CRS, a global authority in drug delivery science. This award not only reflects the quality of our research but provides strong third-party validation of the scientific underpinnings of ChemoSeed. It reinforces the promise of our platform to deliver targeted, sustained therapeutic action directly at the tumour site in glioblastoma patients. This accolade highlights the innovative potential of ChemoSeed and its ability to redefine treatment delivery for solid tumours. It is a testament to our team's commitment to advancing safer, more effective therapies."
The full article is available in the February 2024 issue of Drug Delivery and Translational Research, published by Springer and at the following link https://link.springer.com/article/10.1007/s13346-024-01524-x
-Ends-
Enquiries:
Company | Nomad and Broker | Financial PR |
CRISM Therapeutics Corporation | S.P. Angel Corporate Finance LLP | Burson Buchanan |
Andrew Webb, CEO Chris McConville, CSO | Richard Morrison Adam Cowl | Mark Court / Jamie Hooper CRISM@buchanancomms.co.uk |
via Burson Buchanan | +44 (0) 20 3470 0470 | +44 (0) 20 7466 5000 |
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.
CRISM is expects to submit a clinical trial application for ChemoSeed glioblastoma in H2 2025.
For more information please visit: https://www.crismtherapeutics.com/
For more information on the Controlled Release Society, please visit: https://www.controlledreleasesociety.org/
Follow the stocks
